ClinicalTrials.gg
CompletedNCT01524783RADIANT-4Updated Aug 5, 2021Results posted

Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin)

A Phase 3 interventional study of Everolimus and Placebo in Advanced NET of GI Origin, Advanced NET of Lung Origin and Neuroendocrine Tumors, sponsored by Novartis Pharmaceuticals. Completed at 97 sites in 25 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-08-05.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
302
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing everolimus in Neuroendocrine Tumors — 1 open to participants now, 2 under way, none of them phase 3. Everolimus · Neuroendocrine Tumors.

Enrollment
Largest of 22
302 · median 38
Started
2012
with 3 others
Phase 3
2 of 22
none open now
Registered
10th of 22
by date
Lead sponsor
8 of 22
Novartis Pharmaceuticals

Among the 22 studies testing everolimus in Neuroendocrine Tumors, this one has the largest enrollment, is one of 4 that started in 2012, is one of 2 in phase 3, and was the 10th registered.

Neuroendocrine Tumors

543 studies on the registry are indexed under Neuroendocrine Tumors; 136 are open to participants now.

Browse Neuroendocrine Tumors studies →

Open to participants now

1 of the 22 studies testing everolimus in Neuroendocrine Tumors is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About everolimus

Everolimus: first FDA approval 2009 (AFINITOR), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 112 Neuroendocrine Tumors studies recruiting now, 73 (65%) set no upper age limit and 17 (15%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing everolimus in Neuroendocrine Tumors, or all of them as a file.
02

Study summary

The purpose of this study is to compare the antitumor activity of everolimus plus best supportive care versus placebo plus best supportive care in patients with progressive nonfunctional neuroendocrine tumor (NET) of gastrointestinal (GI) or lung origin without a history of, or current symptoms of carcinoid syndrome.

Read the detailed description

This was a prospective, multi-center, randomized, double-blind, parallel-group, placebo-controlled, two-arm Phase III study comparing the efficacy and safety of everolimus 10 mg daily to placebo in patients with advanced NET of GI or lung origin without a history of, or current symptoms of carcinoid syndrome.

After assessment of eligibility, participants qualifying for the study were randomized in a 2:1 ratio to receive either everolimus or matching placebo. Participants received daily oral doses of 10 mg everolimus or matching placebo as study drug. In both arms, the study drug was combined with best supportive care and treatment cycles were defined as 28 days. Participants were treated until disease progression as per Response Evaluation Criteria In Solid Tumors (RECIST) 1.0, intolerable toxicity, death, lost to follow-up or consent withdrawal. Regardless of the reason for study drug discontinuation, participants had a safety follow-up visit scheduled 30 days after the last dose of the study drug.

Per data monitoring committee recommendation, all participants on treatment with placebo were allowed to crossover to open-label treatment with everolimus. This change was implemented through protocol amendment 3 (issued on 06-May-2016) after which remaining participants entered into open-label phase of the study.

03

Conditions studied

  • Advanced NET of GI Origin
  • Advanced NET of Lung Origin
  • Neuroendocrine Tumors

Browse trials for

Keywords

  • Neuroendocrine tumor
  • NET
  • progressive
  • advanced
  • gastrointestinal
  • GI or lung origin
  • nonfunctional
  • everolimus
  • Advanced NET of GI origin
  • Advanced NET of lung origin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed, well differentiated (G1 or G2), advanced (unresectable or ), neuroendocrine tumor of GI or lung origin
  • No history of and no active symptoms related to carcinoid syndrome
  • In addition to treatment-naive patients, patients previously treated with SSA, Interferon (IFN), one , and/or PRRT were allowed into the study. Pretreated patients had to have progressed on or after the last treatment
  • Radiological documented disease progression within 6 months prior to randomization
  • ≤1
  • Adequate bone marrow, liver and renal function

Exclusion criteria

Exclusion Criteria:

  • Patients with poorly differentiated neuroendocrine carcinoma, high-grade neuroendocrine carcinoma, adenocarcinoid, pancreatic islet cell carcinoma, insulinoma, glucagonoma, gastrinoma, goblet cell carcinoid, large cell neuroendocrine carcinoma and small cell carcinoma
  • Patients with pancreatic NET or NET of origins other than GI or Lung
  • Patients with history of or active symptoms of carcinoid syndrome (e.g. flushing, diarrhea)
  • Patients with more than one
  • Prior targeted therapy
  • Hepatic intra-arterial embolization within the last 6 months. Cryoablation or radiofrequency ablation of hepatic within 2 months of randomization
  • Prior therapy with mTOR inhibitors (e.g. sirolimus, temsirolimus, deforolimus)
  • Known intolerance or to everolimus or other rapamycin analogs (e.g. sirolimus, temsirolimus)
  • Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus
  • Uncontrolled diabetes mellitus as defined by >8% despite adequate therapy
  • Patients who had any severe and/or uncontrolled medical conditions such as:

    • unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction ≤6 months prior to randomization, serious uncontrolled cardiac arrhythmia
    • active or uncontrolled severe infection
    • liver disease such as cirrhosis, decompensated liver disease, and chronic hepatitis (i.e. quantifiable and/or positive HbsAg, quantifiable )
  • Chronic treatment with or other agents
  • Known history of seropositivity
  • Pregnant or nursing (lactating) women

Other protocol-defined inclusion/exclusion criteria might apply.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
302 participants (actual)

Study arms

  • Experimental
    Everolimus + BSC

    Participants received everolimus 10 mg once daily plus best supportive care (BSC) throughout the study

    Drug: Everolimus · Other: Best suportive care (BSC)

  • Placebo comparator
    Placebo + BSC

    Participants received matching placebo once daily plus best supportive care (BSC) during the blinded period. Participants were allowed to crossover to treatment with everolimus 10mg once daily plus BSC during the open-label period.

    Drug: Placebo · Other: Best suportive care (BSC)

Interventions

  • Participants were treated with everolimus 10 mg (two 5 mg tablets) once daily orally taken

    Also known as: RAD001

  • DrugPlacebo

    Participants were treated with two tablets of matching placebo once daily orally taken.

  • OtherBest suportive care (BSC)

    Best supportive care includes all care provided to participants deemed necessary by the treating physician, such as but not restricted to anti-diarrheals and analgesics. The optimal care of the patient is based on the treating physician's best medical judgment.

06

What researchers measure

Primary outcomes

  1. Probability of Participants Remaining Event-Free in Progression-Free Survival (PFS) Based on Central Radiology Assessment

    PFS is defined as the time from randomization to the date of the first documented tumor progression or death from any cause, whichever comes first. Progression was defined using modified RECIST 1.0 and as per central radiology assessment as at least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. Progression was assessed by cat scan (CT) and/or magnetic resonance imaging (MRI). For participants who had not progressed or died at the analysis cut-off date, PFS was censored at the date of the last adequate tumor evaluation date. An adequate tumour assessment is a tumour assessment with an overall response other than unknown. The percentage event-free probability estimate is the estimated probability that a patient will remain event-free in PFS up to the specified time point.

    Time frame: From date of randomization to progression or death, whichever comes first, assessed up to 27 months

Secondary outcomes

  1. Overall Survival (OS)

    OS is defined as the time from the date of randomization to date of death due to any cause. If a death had not been observed by the date of analysis cut-off, then OS was censored at the date of last contact. All participants randomized to placebo arm who crossed over to everolimus were censored.

    Time frame: From date of randomization to date of death, assessed up to approximately 8 years

  2. Overall Response Rate (ORR) as Per Modified RECIST 1.0 According to Central Evaluation

    ORR is defined as the proportion of patients with best overall response (BOR) of complete response (CR) or partial response (PR), according to central evaluation and as per modified RECIST 1.0. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of the longest diameter of all target lesions, taking as reference the baseline sum of the longest diameters.

    Time frame: From randomization until end of treatment, assessed up to approximately 2.5 years

  3. Disease Control Rate (DCR) Based on Modified RECIST 1.0 and as Per Central Radiology Assessment

    DCR is defined as the proportion of subjects with best overall response of CR or PR or stable disease based on modified RECIST 1.0 and as per central radiology assessment. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of the longest diameter of all target lesions, taking as reference the baseline sum of the longest diameters. Stable disease: Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progression.

    Time frame: From randomization until end of treatment, assessed up to approximately 2.5 years

  4. Time to Definitive Deterioration in Functional Assessment of Cancer Therapy - General (FACT-G) Questionnaire Total Score

    FACT-G is a self-assessed health-related quality of life questionnaire. The questionnaire is comprised of 27 questions examining physical, social/family, emotional, and functional well-being. Participants responded to the items on a five-point scale, ranging from 0: "Not at all" to 4: "Very much." The total score ranges from 0 to 108, with higher scores indicating a better patient-reported outcome/quality of life. Definitive deterioration is defined as a decrease in the total score by at least 7 points compared to baseline with no further improvement. Death was considered as worsening of the FACT-G total score if it occurred close to the last available assessment, where "close" was defined as twice the planned period between two assessments. Patients without definitive worsening prior to analysis cut-off or prior to start of another anticancer therapy were censored at the date of their last assessment.

    Time frame: From randomization to definitive deterioration of FACT-G total score, assessed up to approximately 3 years

  5. Change From Baseline in Chromogranin A (CgA) Levels

    CgA is a potential biomarker for tumor response. Blood samples were collected for assessment of CgA levels. Change from Baseline at a particular visit was calculated as the CgA level at that visit minus Baseline.

    Time frame: From baseline (every 4 weeks) up to 116 weeks

  6. Change From Baseline in Neuron Specific Enolase (NSE) Levels

    NSE is a potential biomarker for tumor response. Blood samples were collected for assessment of NSE levels. Change from Baseline at a particular visit was calculated as the NSE level at that visit minus Baseline.

    Time frame: From baseline (every 4 weeks) up to Week 116

  7. Time to Definitive Deterioration in World Health Organization (WHO) Performance Status (PS) Change

    WHO PS is a scale rated from 0 (fully active) to 5 (death) by a healthcare professional to assess the overall status of a patient: a lower score represents a higher ability to perform daily tasks. Deterioration is defined as an increase of at least one point compared to baseline. Deterioration is considered definitive if no improvements in the WHO PS status is observed at a subsequent time of measurement during the treatment period following the time point where the deterioration is observed. Death was considered as worsening of the WHO PS if it occurred close to the last available assessment, where "close" was defined as twice the planned period between two assessments. Patients without definitive worsening prior to analysis cut-off or prior to start of another anticancer therapy were censored at the date of their last assessment.

    Time frame: From randomization to definitive deterioration of WHO performance status, assessed up to approximately 3 years

  8. Pharmacokinetics (PK): Predose Concentration (Cmin) of Everolimus at Day 29

    A pre-dose blood sample at day 29 was collected to determine the exposure of everolimus at the steady-state pre-dose concentration (Cmin). Cmin is provided for participants randomized to everolimus+BSC who received 10mg of everolimus daily and also for participants randomized to everolimus+BSC who received 5mg of everolimus daily which was required for a number of participants in the study experiencing adverse events requiring dose modifications

    Time frame: Pre-dose at Day 29.

07

Results

Posted Dec 28, 2016

Participant flow

Blinded Period
Participant flow — Blinded Period
MilestoneEverolimus + BSC (Throughout Study)Placebo+BSC (Blinded Period)Everolimus+BSC (Crossover)
Started205970
Completed2660
Not completed179910
Withdrew: Adverse event6470
Withdrew: Disease progression89750
Withdrew: Withdrawal by subject1960
Withdrew: Protocol deviation210
Withdrew: Death520
Open-label Period
Participant flow — Open-label Period
MilestoneEverolimus + BSC (Throughout Study)Placebo+BSC (Blinded Period)Everolimus+BSC (Crossover)
Started2606
Completed000
Not completed2606
Withdrew: Disease progression1302
Withdrew: Administrative problems502
Withdrew: Adverse event501
Withdrew: Withdrawal by subject201
Withdrew: Protocol deviation100

Outcome measures

PrimaryProbability of Participants Remaining Event-Free in Progression-Free Survival (PFS) Based on Central Radiology Assessment

PFS is defined as the time from randomization to the date of the first documented tumor progression or death from any cause, whichever comes first. Progression was defined using modified RECIST 1.0 and as per central radiology assessment as at least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. Progression was assessed by cat scan (CT) and/or magnetic resonance imaging (MRI). For participants who had not progressed or died at the analysis cut-off date, PFS was censored at the date of the last adequate tumor evaluation date. An adequate tumour assessment is a tumour assessment with an overall response other than unknown. The percentage event-free probability estimate is the estimated probability that a patient will remain event-free in PFS up to the specified time point.

Time frame:
From date of randomization to progression or death, whichever comes first, assessed up to 27 months
Reported as:
Number · Percent event-free probability in PFS
Probability of Participants Remaining Event-Free in Progression-Free Survival (PFS) Based on Central Radiology Assessment
Percent event-free probability in PFSEverolimus + BSCPlacebo + BSC
2 months90.1 (84.8 to 93.5)74.6 (64.3 to 82.4)
4 months81.2 (74.9 to 86.2)49.1 (38.1 to 59.2)
6 months72.1 (65.0 to 78.0)40.1 (29.5 to 50.5)
8 months62.4 (54.8 to 69.1)35.8 (25.4 to 46.2)
10 months51.7 (44.0 to 59.0)31.3 (21.3 to 41.7)
12 months44.4 (36.7 to 51.8)28.1 (18.5 to 38.6)
15 months40.1 (32.5 to 47.6)26.4 (16.9 to 36.8)
18 months31.8 (24.1 to 39.8)24.4 (15.0 to 34.9)
21 months27.6 (19.0 to 36.8)17.4 (9.0 to 28.2)
24 months22.0 (13.0 to 32.5)17.4 (9.0 to 28.2)
27 monthsNA (NA to NA)17.4 (9.0 to 28.2)
Statistical analysis
  • Everolimus + BSC vs Placebo + BSC · Log Rank · p = <0.001 · Hazard ratio (hr): 0.48 · 95% CI 0.35 to 0.67
SecondaryOverall Survival (OS)

OS is defined as the time from the date of randomization to date of death due to any cause. If a death had not been observed by the date of analysis cut-off, then OS was censored at the date of last contact. All participants randomized to placebo arm who crossed over to everolimus were censored.

Time frame:
From date of randomization to date of death, assessed up to approximately 8 years
Reported as:
Median · Months
Overall Survival (OS)
MonthsEverolimus + BSCPlacebo + BSC
Overall Survival (OS)43.1 (36.27 to 54.24)41.76 (23.46 to 53.75)
Statistical analysis
  • Everolimus + BSC vs Placebo + BSC · Log Rank · p = 0.259 · Hazard ratio (hr): 0.90 · 95% CI 0.66 to 1.24
SecondaryOverall Response Rate (ORR) as Per Modified RECIST 1.0 According to Central Evaluation

ORR is defined as the proportion of patients with best overall response (BOR) of complete response (CR) or partial response (PR), according to central evaluation and as per modified RECIST 1.0. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of the longest diameter of all target lesions, taking as reference the baseline sum of the longest diameters.

Time frame:
From randomization until end of treatment, assessed up to approximately 2.5 years
Reported as:
Number · Percentage of participants
Overall Response Rate (ORR) as Per Modified RECIST 1.0 According to Central Evaluation
Percentage of participantsEverolimus + BSCPlacebo + BSC
Overall Response Rate (ORR) as Per Modified RECIST 1.0 According to Central Evaluation2.0 (0.5 to 4.9)1.0 (0.0 to 5.6)
SecondaryDisease Control Rate (DCR) Based on Modified RECIST 1.0 and as Per Central Radiology Assessment

DCR is defined as the proportion of subjects with best overall response of CR or PR or stable disease based on modified RECIST 1.0 and as per central radiology assessment. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of the longest diameter of all target lesions, taking as reference the baseline sum of the longest diameters. Stable disease: Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progression.

Time frame:
From randomization until end of treatment, assessed up to approximately 2.5 years
Reported as:
Number · Percentage of participants
Disease Control Rate (DCR) Based on Modified RECIST 1.0 and as Per Central Radiology Assessment
Percentage of participantsEverolimus + BSCPlacebo + BSC
Disease Control Rate (DCR) Based on Modified RECIST 1.0 and as Per Central Radiology Assessment82.4 (76.5 to 87.4)64.9 (54.6 to 74.4)
SecondaryTime to Definitive Deterioration in Functional Assessment of Cancer Therapy - General (FACT-G) Questionnaire Total Score

FACT-G is a self-assessed health-related quality of life questionnaire. The questionnaire is comprised of 27 questions examining physical, social/family, emotional, and functional well-being. Participants responded to the items on a five-point scale, ranging from 0: "Not at all" to 4: "Very much." The total score ranges from 0 to 108, with higher scores indicating a better patient-reported outcome/quality of life. Definitive deterioration is defined as a decrease in the total score by at least 7 points compared to baseline with no further improvement. Death was considered as worsening of the FACT-G total score if it occurred close to the last available assessment, where "close" was defined as twice the planned period between two assessments. Patients without definitive worsening prior to analysis cut-off or prior to start of another anticancer therapy were censored at the date of their last assessment.

Time frame:
From randomization to definitive deterioration of FACT-G total score, assessed up to approximately 3 years
Reported as:
Median · Months
Time to Definitive Deterioration in Functional Assessment of Cancer Therapy - General (FACT-G) Questionnaire Total Score
MonthsEverolimus + BSCPlacebo + BSC
Time to Definitive Deterioration in Functional Assessment of Cancer Therapy - General (FACT-G) Questionnaire Total Score13.01 (9.33 to 24.80)9.23 (5.52 to 28.62)
Statistical analysis
  • Everolimus + BSC vs Placebo + BSC · Log Rank · p = 0.073 · Hazard ratio (hr): 0.74 · 95% CI 0.50 to 1.10
SecondaryChange From Baseline in Chromogranin A (CgA) Levels

CgA is a potential biomarker for tumor response. Blood samples were collected for assessment of CgA levels. Change from Baseline at a particular visit was calculated as the CgA level at that visit minus Baseline.

Time frame:
From baseline (every 4 weeks) up to 116 weeks
Reported as:
Mean · microgram/liter (ug/L)
Change From Baseline in Chromogranin A (CgA) Levels
microgram/liter (ug/L)Everolimus + BSCPlacebo + BSC
Week 4434.8 ± 2306.701154.3 ± 9083.39
Week 8162.3 ± 2550.652697.6 ± 19956.90
Week 12396.7 ± 2401.781176.0 ± 3322.13
Week 16263.5 ± 2946.761450.4 ± 4825.78
Week 20162.1 ± 2464.473640.1 ± 12653.42
Week 24253.2 ± 3487.271783.9 ± 5399.98
Week 28587.2 ± 4861.351350.3 ± 5701.70
Week 32508.5 ± 6102.612000.7 ± 6362.83
Week 3694.7 ± 4905.17180.9 ± 383.93
Week 40511.4 ± 6180.67207.6 ± 403.30
Week 44552.8 ± 4173.44140.6 ± 328.02
Week 481326.2 ± 8718.92129.0 ± 326.69
Week 521196.2 ± 7737.76124.2 ± 452.38
Week 561920.6 ± 11250.07134.9 ± 346.33
Week 601722.0 ± 13155.03120.9 ± 415.73
Week 643811.0 ± 26656.45141.6 ± 281.38
Week 681413.3 ± 9588.68222.6 ± 333.93
Week 72239.5 ± 2318.79233.7 ± 400.43
Week 763256.5 ± 19395.40210.9 ± 522.62
Week 805421.0 ± 32471.22286.3 ± 425.45
Week 844379.9 ± 28302.84175.4 ± 575.98
Week 88571.2 ± 2694.44-9.4 ± 473.66
Week 92765.5 ± 2913.1563.7 ± 477.53
Week 96984.6 ± 3379.28146.5 ± 468.24
Week 100935.3 ± 2961.60-12.7 ± 399.25
Week 1041466.4 ± 4257.03-21.7 ± 285.99
Week 1082245.8 ± 6077.99215.9 ± 293.87
Week 1122817.0 ± 7786.28514.5 ± 661.80
Week 1162951.8 ± 6745.0699.6 ± 92.91
SecondaryChange From Baseline in Neuron Specific Enolase (NSE) Levels

NSE is a potential biomarker for tumor response. Blood samples were collected for assessment of NSE levels. Change from Baseline at a particular visit was calculated as the NSE level at that visit minus Baseline.

Time frame:
From baseline (every 4 weeks) up to Week 116
Reported as:
Mean · microgram/liter (ug/L)
Change From Baseline in Neuron Specific Enolase (NSE) Levels
microgram/liter (ug/L)Everolimus + BSCPlacebo + BSC
Week 40.1 ± 5.21-2.2 ± 39.87
Week 80.3 ± 8.71-4.2 ± 36.71
Week 12-0.3 ± 8.3715.5 ± 163.75
Week 162.0 ± 8.344.1 ± 19.44
Week 200.8 ± 6.215.3 ± 18.26
Week 241.7 ± 8.996.7 ± 23.47
Week 281.1 ± 6.370.4 ± 9.16
Week 321.5 ± 14.243.1 ± 8.96
Week 362.0 ± 15.112.0 ± 5.90
Week 401.2 ± 6.481.2 ± 4.49
Week 440.8 ± 5.101.2 ± 4.46
Week 482.0 ± 9.200.6 ± 4.06
Week 521.5 ± 5.820.7 ± 4.19
Week 563.6 ± 18.560.9 ± 5.89
Week 602.4 ± 8.190.1 ± 3.35
Week 644.4 ± 23.220.9 ± 3.80
Week 681.1 ± 4.681.9 ± 4.48
Week 721.6 ± 4.460.7 ± 3.91
Week 761.7 ± 5.110.6 ± 3.89
Week 802.9 ± 10.150.7 ± 2.83
Week 848.0 ± 33.130.1 ± 3.47
Week 882.2 ± 3.890.6 ± 2.47
Week 924.0 ± 7.240.1 ± 3.79
Week 964.3 ± 5.960.0 ± 2.99
Week 1001.8 ± 3.79-0.2 ± 5.10
Week 1042.9 ± 4.11-1.7 ± 4.76
Week 1085.5 ± 13.48-0.5 ± 4.33
Week 1122.8 ± 5.72-3.2 ± 3.30
Week 11610.6 ± 14.920.2 ± 4.17
SecondaryTime to Definitive Deterioration in World Health Organization (WHO) Performance Status (PS) Change

WHO PS is a scale rated from 0 (fully active) to 5 (death) by a healthcare professional to assess the overall status of a patient: a lower score represents a higher ability to perform daily tasks. Deterioration is defined as an increase of at least one point compared to baseline. Deterioration is considered definitive if no improvements in the WHO PS status is observed at a subsequent time of measurement during the treatment period following the time point where the deterioration is observed. Death was considered as worsening of the WHO PS if it occurred close to the last available assessment, where "close" was defined as twice the planned period between two assessments. Patients without definitive worsening prior to analysis cut-off or prior to start of another anticancer therapy were censored at the date of their last assessment.

Time frame:
From randomization to definitive deterioration of WHO performance status, assessed up to approximately 3 years
Reported as:
Median · Months
Time to Definitive Deterioration in World Health Organization (WHO) Performance Status (PS) Change
MonthsEverolimus + BSCPlacebo + BSC
Time to Definitive Deterioration in World Health Organization (WHO) Performance Status (PS) Change24.08 (17.05 to NA)24.15 (8.31 to NA)
Statistical analysis
  • Everolimus + BSC vs Placebo + BSC · Log Rank · p = 0.539 · Hazard ratio (hr): 1.02 · 95% CI 0.65 to 1.61
SecondaryPharmacokinetics (PK): Predose Concentration (Cmin) of Everolimus at Day 29

A pre-dose blood sample at day 29 was collected to determine the exposure of everolimus at the steady-state pre-dose concentration (Cmin). Cmin is provided for participants randomized to everolimus+BSC who received 10mg of everolimus daily and also for participants randomized to everolimus+BSC who received 5mg of everolimus daily which was required for a number of participants in the study experiencing adverse events requiring dose modifications

Time frame:
Pre-dose at Day 29.
Reported as:
Mean · nanogram/milliliter (ng/mL)
Pharmacokinetics (PK): Predose Concentration (Cmin) of Everolimus at Day 29
nanogram/milliliter (ng/mL)Everolimus + BSC
10mg daily dose16.382 ± 13.2767
5mg daily dose4.700 ± 3.8396
Post-hocAll Collected Deaths

Deaths on-treatment were collected from first dose of study treatment until end of study treatment plus 30 days post treatment, up to maximum duration of approximately 8 years. Total Deaths were collected from first dose of study treatment until end of post-treatment survival follow, up to maximum duration of approximately 8 years.

Time frame:
On-treatment deaths: up to approximately 8 years. All deaths: up to approximately 8 years
Reported as:
Number · Participants
All Collected Deaths
ParticipantsEverolimus + BSC (Throughout the Study)Everolimus +BSC (Crossover)Everolimus+BSC (All)Placebo + BSC (Blinded Period)
On-treatment deaths100105
Total deaths126112757

Adverse events

Collected over Adverse events and all-cause mortality were collected from date of first dose of study treatment until end of study treatment plus 30 days post treatment, assessed up to a maximum duration of approximately 8 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Everolimus+BSC (Throughout Study)10/202 (5%)93/202 (46%)197/202 (97.5%)
Everolimus +BSC (Crossover)0/6 (0%)1/6 (16.7%)6/6 (100%)
Everolimus+BSC (All)10/208 (4.8%)94/208 (45.2%)203/208 (97.6%)
Placebo+BSC (Blinded Period)5/98 (5.1%)21/98 (21.4%)81/98 (82.7%)
Most frequent serious events
Showing 10 of 147
Most frequent serious events
EventEverolimus+BSC (Throughout Study)Everolimus +BSC (Crossover)Everolimus+BSC (All)Placebo+BSC (Blinded Period)
Abdominal painGastrointestinal disorders13/2021/614/2084/98
Small intestinal obstructionGastrointestinal disorders6/2021/67/2080/98
HypokalaemiaMetabolism and nutrition disorders3/2021/64/2080/98
PyrexiaGeneral disorders11/2020/611/2081/98
DiarrhoeaGastrointestinal disorders10/2020/610/2080/98
AnaemiaBlood and lymphatic system disorders7/2020/67/2080/98
FatigueGeneral disorders7/2020/67/2080/98
PneumoniaInfections and infestations7/2020/67/2081/98
Acute kidney injuryRenal and urinary disorders4/2020/64/2083/98
AstheniaGeneral disorders6/2020/66/2080/98
Most frequent other events
Showing 10 of 95
Most frequent other events
EventEverolimus+BSC (Throughout Study)Everolimus +BSC (Crossover)Everolimus+BSC (All)Placebo+BSC (Blinded Period)
StomatitisGastrointestinal disorders113/2022/6115/20819/98
Aphthous ulcerGastrointestinal disorders8/2023/611/2082/98
DiarrhoeaGastrointestinal disorders88/2023/691/20830/98
HypokalaemiaMetabolism and nutrition disorders21/2023/624/2084/98
RashSkin and subcutaneous tissue disorders62/2023/665/2089/98
Oedema peripheralGeneral disorders81/2021/682/2085/98
FatigueGeneral disorders76/2022/678/20836/98
VertigoEar and labyrinth disorders3/2022/65/2082/98
ConstipationGastrointestinal disorders25/2022/627/20819/98
ToothacheGastrointestinal disorders11/2022/613/2083/98

Baseline characteristics

Age, Continuous
Age, Continuous(years)Everolimus + BSCPlacebo+BSCTotal
Mean62.9 ± 11.7059.4 ± 12.8961.7 ± 12.18
Sex: Female, Male
Sex: Female, Male(Participants)Everolimus + BSCPlacebo+BSCTotal
Female11644160
Male8953142
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Everolimus + BSCPlacebo+BSCTotal
Caucasian16268230
Asian321850
Black6915
Other527
08

Study locations

97 sites
  • University of California San Diego - Moores Cancer Center Regulatory
    La Jolla, California 92093-0658, United States
  • Scripps Clinic Regulatory
    La Jolla, California 92121, United States
  • Cedars Sinai Medical Center SC
    Los Angeles, California 90048, United States
  • University of Colorado Cancer Centre SC
    Aurora, Colorado 80045, United States
  • H Lee Moffitt Cancer Center and Research Institute HLM
    Tampa, Florida 33612, United States
  • University of Chicago UC SC
    Chicago, Illinois 60637, United States
  • Goshen Center for Cancer Care IU Health SC
    Indianapolis, Indiana 46202, United States
  • Dana Farber Cancer Institute SC
    Boston, Massachusetts 02215, United States
  • Montefiore Medical Center MMC
    Bronx, New York 10467, United States
  • Memorial Sloan Kettering MSkCC SC
    New York, New York 10017, United States
  • Oregon Health and Science University OH&SU
    Portland, Oregon 97239, United States
  • Vanderbilt University Medical Center Vanderbilt Med Ctr
    Nashville, Tennessee 37232, United States
  • Texas Oncology P A Texas Oncology Amarillo
    Dallas, Texas 75251, United States
  • Texas Oncology P A TX Oncology Baylor
    Dallas, Texas 75251, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • University of Texas MD Anderson Cancer Center UT MD Anderson Cancer Ctr
    Houston, Texas 77030, United States
  • University of Wisconsin / Paul P. Carbone Comp Cancer Center Univ Wisc
    Madison, Wisconsin 53792-6164, United States
  • Novartis Investigative Site
    Innsbruck, Tyrol 6020, Austria
  • Novartis Investigative Site
    Wien, A-1090, Austria
  • Novartis Investigative Site
    Edegem, Antwerpen 2650, Belgium
  • Novartis Investigative Site
    Bruxelles, 1200, Belgium
  • Novartis Investigative Site
    Gent, 9000, Belgium
  • Novartis Investigative Site
    Leuven, 3000, Belgium
  • Novartis Investigative Site
    Calgary, Alberta T2N 4N2, Canada
  • Novartis Investigative Site
    Vancouver, British Columbia V5Z 4E6, Canada
  • Novartis Investigative Site
    Halifax, Nova Scotia B3H 1V7, Canada
  • Novartis Investigative Site
    London, Ontario N6A 4L6, Canada
  • Novartis Investigative Site
    Ottawa, Ontario K1H 8L6, Canada
  • Novartis Investigative Site
    Toronto, Ontario M4N 3M5, Canada
  • Novartis Investigative Site
    Montreal, Quebec H1T 2M4, Canada
  • Novartis Investigative Site
    Beijing, Beijing 100730, China
  • Novartis Investigative Site
    Beijing, 100021, China
  • Novartis Investigative Site
    Beijing, 100029, China
  • Novartis Investigative Site
    Beijing, 100036, China
  • Novartis Investigative Site
    Beijing, 100039, China
  • Novartis Investigative Site
    Bogotá, Cundinamarca, Colombia
  • Novartis Investigative Site
    Brno, 65653, Czechia
  • Novartis Investigative Site
    Olomouc, 775 20, Czechia
  • Novartis Investigative Site
    Praha, 12808, Czechia
  • Novartis Investigative Site
    Bad Berka, 99438, Germany
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Essen, 45147, Germany
  • Novartis Investigative Site
    Frankfurt, 60590, Germany
  • Novartis Investigative Site
    Hannover, 30625, Germany
  • Novartis Investigative Site
    Magdeburg, 39120, Germany
  • Novartis Investigative Site
    Mainz, 55131, Germany
  • Novartis Investigative Site
    Athens, 115 27, Greece
  • Novartis Investigative Site
    Budapest, 1062, Hungary
  • Novartis Investigative Site
    Budapest, 1085, Hungary
  • Novartis Investigative Site
    Bologna, BO 40138, Italy
  • Novartis Investigative Site
    Brescia, BS 25123, Italy
  • Novartis Investigative Site
    Viagrande, CT 95029, Italy
  • Novartis Investigative Site
    Firenze, FI 50134, Italy
  • Novartis Investigative Site
    Milano, MI 20133, Italy
  • Novartis Investigative Site
    Milano, MI 20141, Italy
  • Novartis Investigative Site
    Rozzano, MI 20089, Italy
  • Novartis Investigative Site
    Modena, MO 41124, Italy
  • Novartis Investigative Site
    Roma, RM 00168, Italy
  • Novartis Investigative Site
    Roma, RM 00189, Italy
  • Novartis Investigative Site
    Verona, VR 37126, Italy
  • Novartis Investigative Site
    Napoli, 80131, Italy
  • Novartis Investigative Site
    Napoli, 80132, Italy
  • Novartis Investigative Site
    Fukuoka city, Fukuoka 812-8582, Japan
  • Novartis Investigative Site
    Osaka-city, Osaka 553-0003, Japan
  • Novartis Investigative Site
    Chuo ku, Tokyo 104 0045, Japan
  • Novartis Investigative Site
    Seoul, Korea 05505, Korea, Republic of
  • Novartis Investigative Site
    Seoul, Seocho Gu 06591, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 03080, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 03722, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 06351, Korea, Republic of
  • Novartis Investigative Site
    Ashrafieh, 166830, Lebanon
  • Novartis Investigative Site
    Beirut, 1107 2020, Lebanon
  • Novartis Investigative Site
    Amsterdam, 1066 CX, Netherlands
  • Novartis Investigative Site
    Gliwice, Slaskie 44-101, Poland
  • Novartis Investigative Site
    Poznan, 60-355, Poland
  • Novartis Investigative Site
    Rostov-na-Donu, 344037, Russian Federation
  • Novartis Investigative Site
    Riyadh, 11211, Saudi Arabia
  • Novartis Investigative Site
    Bratislava, Slovak Republic 833 10, Slovakia
  • Novartis Investigative Site
    Parktown, 2193, South Africa
  • Novartis Investigative Site
    Sevilla, Andalucia 41009, Spain
  • Novartis Investigative Site
    Barcelona, Catalunya 08035, Spain
  • Novartis Investigative Site
    Hospitalet de LLobregat, Catalunya 08907, Spain
  • Novartis Investigative Site
    Taipei, Taiwan, ROC 11217, Taiwan
  • Novartis Investigative Site
    Kuei-Shan Chiang, Taoyuan/ Taiwan ROC 33305, Taiwan
  • Novartis Investigative Site
    Kaohsiung, 833, Taiwan
  • Novartis Investigative Site
    Taichung, 40705, Taiwan
  • Novartis Investigative Site
    Taipei, 10048, Taiwan
  • Novartis Investigative Site
    Bangkok, THA 10330, Thailand
  • Novartis Investigative Site
    Chiang Mai, 50200, Thailand
  • Novartis Investigative Site
    Gaziantep, 27310, Turkey
  • Novartis Investigative Site
    Istanbul, 34303, Turkey
  • Novartis Investigative Site
    Glasgow, Scotland G12 0YN, United Kingdom
  • Novartis Investigative Site
    Cambridge, CB2 2QQ, United Kingdom
  • Novartis Investigative Site
    London, SE1 9RT, United Kingdom
  • Novartis Investigative Site
    London, W12 0HS, United Kingdom
  • Novartis Investigative Site
    Manchester, M20 2BX, United Kingdom
  • Novartis Investigative Site
    Southampton, SO16 6YD, United Kingdom
09

References and documents

Publications

  • Chan DL, Yao JC, Carnaghi C, Buzzoni R, Herbst F, Ridolfi A, Strosberg J, Kulke MH, Pavel M, Singh S. Markers of Systemic Inflammation in Neuroendocrine Tumors: A Pooled Analysis of the RADIANT-3 and RADIANT-4 Studies. Pancreas. 2021 Feb 1;50(2):130-137. doi: 10.1097/MPA.0000000000001745. PubMed 33560090 ↗
  • Buzzoni R, Carnaghi C, Strosberg J, Fazio N, Singh S, Herbst F, Ridolfi A, Pavel ME, Wolin EM, Valle JW, Oh DY, Yao JC, Pommier R. Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4. Onco Targets Ther. 2017 Oct 16;10:5013-5030. doi: 10.2147/OTT.S142087. eCollection 2017. PubMed 29081664 ↗
  • Fazio N, Buzzoni R, Delle Fave G, Tesselaar ME, Wolin E, Van Cutsem E, Tomassetti P, Strosberg J, Voi M, Bubuteishvili-Pacaud L, Ridolfi A, Herbst F, Tomasek J, Singh S, Pavel M, Kulke MH, Valle JW, Yao JC. Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis. Cancer Sci. 2018 Jan;109(1):174-181. doi: 10.1111/cas.13427. Epub 2017 Nov 9. PubMed 29055056 ↗
  • Pavel ME, Singh S, Strosberg JR, Bubuteishvili-Pacaud L, Degtyarev E, Neary MP, Carnaghi C, Tomasek J, Wolin E, Raderer M, Lahner H, Valle JW, Pommier R, Van Cutsem E, Tesselaar MET, Fave GD, Buzzoni R, Hunger M, Eriksson J, Cella D, Ricci JF, Fazio N, Kulke MH, Yao JC. Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 Oct;18(10):1411-1422. doi: 10.1016/S1470-2045(17)30471-0. Epub 2017 Aug 30. PubMed 28838862 ↗
  • Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, Tomasek J, Raderer M, Lahner H, Voi M, Pacaud LB, Rouyrre N, Sachs C, Valle JW, Fave GD, Van Cutsem E, Tesselaar M, Shimada Y, Oh DY, Strosberg J, Kulke MH, Pavel ME; RAD001 in Advanced Neuroendocrine Tumours, Fourth Trial (RADIANT-4) Study Group. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016 Mar 5;387(10022):968-977. doi: 10.1016/S0140-6736(15)00817-X. Epub 2015 Dec 17. PubMed 26703889 ↗

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2012 to primary completion in Nov 2014, 31 months.

Results were first posted in Dec 2016, 2 years 1 month after primary completion.

Of 25 phase 3 interventional studies under Neuroendocrine Tumors, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 85. This study's 31 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2011
First posted
Feb 2, 2012
StartActual
Mar 30, 2012
Primary completionActual
Nov 28, 2014
CompletionActual
Aug 7, 2020
Results first posted
Dec 28, 2016
Last update
Aug 5, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01524783
Responsible party
Sponsor
First posted
Feb 2, 2012
Start date
Mar 30, 2012
Primary completion
Nov 28, 2014
Completion
Aug 7, 2020
Results posted
Dec 28, 2016
Last update
Aug 5, 2021

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Everolimus

Start the discussion